ACP
CRVS icon

Acuta Capital Partners’s Corvus Pharmaceuticals CRVS Stock Holding History

Acuta Capital Partners’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-74,307
Closed -$398K – 37
2024
Q4 		$398K Buy
+74,307
New +$555K 0.4% 36

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acuta Capital Partners's CRVS Position: Q1 2025 in Review

Acuta Capital Partners sold out of Corvus Pharmaceuticals (CRVS) in Q1 2025, closing a stake of 74,307 shares — an estimated $398K sold.

Acuta Capital Partners first reported a position in CRVS in Q4 2024 and held it in 1 quarter. The position peaked at $398K in Q4 2024. 88 funds tracked by Wall St. Rank hold CRVS as of Q1 2025.

  • Acuta Capital Partners reported no remaining Corvus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Acuta Capital Partners sold 74,307 Corvus Pharmaceuticals shares in Q1 2025, an estimated $398K.
  • Acuta Capital Partners first reported a position in Corvus Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Acuta Capital Partners's Corvus Pharmaceuticals position peaked at $398K in Q4 2024.
  • 88 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2025.

Based on Acuta Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.